The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

被引：2

作者：

Horwitz, Steven M. ^{[1
]}

O'Connor, Owen A. ^{[2
]}

Pro, Barbara ^{[3
]}

Illidge, Tim M. ^{[4
]}

Fanale, Michelle A. ^{[5
]}

Advani, Ranjana H. ^{[6
]}

Bartlett, Nancy L. ^{[7
]}

Christensen, Jacob Haaber ^{[8
]}

Morschhauser, Franck ^{[9
]}

Domingo-Domenech, Eva ^{[10
]}

Rossi, Giuseppe ^{[11
]}

Kim, Won Seog ^{[12
]}

Feldman, Tatyana A. ^{[13
]}

Lennard, Anne ^{[14
]}

Belada, David ^{[15
,16
]}

Illes, Arpad ^{[17
]}

Tobinai, Kensei ^{[18
]}

Tsukasaki, Kunihiro ^{[19
]}

Yeh, Su-Peng ^{[20
]}

Shustov, Andrei R. ^{[21
]}

Huettmann, Andreas ^{[22
]}

Savage, Kerry J. ^{[23
,24
]}

Yuen, Sam ^{[25
]}

Zinzani, Pier Luigi ^{[26
]}

Hua, Zhaowei ^{[27
]}

Little, Meredith ^{[27
]}

Rao, Shangbang ^{[28
]}

Woolery, Joseph ^{[28
]}

Manley, Thomas ^{[29
]}

Truemper, Lorenz ^{[30
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Basking Ridge, NJ USA

[2] Columbia Univ, Med Ctr, New York, NY USA

[3] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol & Oncol, Chicago, IL 60611 USA

[4] Univ Manchester, Christie Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Canc Sci,Fac Biol Med & Hlth,NIHR Biomed Res, Manchester, Lancs, England

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Stanford Canc Ctr, Blood & Marrow Transplant Program, Stanford, CA USA

[7] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[8] Odense Univ Hosp, Odense, Denmark

[9] CHRU Lille, Lille, Nord Pas De Cal, France

[10] Inst Catala Oncol, Barcelona, Spain

[11] Azienda Osped Spedali Civili Brescia, Brescia, Italy

[12] Samsung Med Ctr, Seoul, South Korea

[13] Hackensack Univ Med Ctr, Hackensack, NJ USA

[14] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[15] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[16] Charles Univ Prague, Fac Med, Prague, Czech Republic

[17] Debreceni Egyet, Debrecen, Hungary

[18] Natl Canc Ctr, Tokyo, Japan

[19] Saitama Med Univ, Dept Hematol, Int Med Ctr, Saitama, Japan

[20] China Med Univ Hosp, Taichung, Taiwan

[21] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[22] Univ Klinikum Essen, Essen, Germany

[23] Univ British Columbia, Vancouver, BC, Canada

[24] British Columbia Canc Agcy, Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada

[25] Calvary Mater Newcastle Hosp, Newcastle, NSW, Australia

[26] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[27] Takeda Pharmaceut Int Co, Cambridge, MA USA

[28] Seattle Genet, Bothell, WA USA

[29] Seattle Genet Inc, Bothell, WA USA

[30] Univ Med Gottingen, Gottingen, Germany

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110563

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

997

引用

页数：5

共 50 条

[41] Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial
Dou, Jingtao
Ma, Jianhua
Liu, Jun
Wang, Changjiang
Johnsson, Eva
Yao, Hui
Zhao, June
Pan, Changyu
DIABETES OBESITY & METABOLISM, 2018, 20 (03): : 590 - 598
[42] Everolimus plus Octreotide LAR versus Placebo plus Octreotide LAR in Patients with Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Pavel, M.
Peeters, M.
Hoersch, D.
Van Cutsem, E.
Oberg, K.
Jehl, V
Klimovsky, J.
Yao, J.
NEUROENDOCRINOLOGY, 2011, 94 : 38 - 39
[43] A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naive Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma
Xu, Pengpeng
Fan, Ni
Tian, Yamin
Tang, Xinran
Zhang, Bin
Zhou, Wei
Zhao, Renbin
Zhao, Weili
BLOOD, 2022, 140 : 12110 - 12110
[44] Lusutrombopag for Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Who Are Undergoing Non-Emergency Invasive Procedures: Results from An International Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (L-PLUS 2)
Afdhal, Nezam H.
Duggal, Ajay
Ochiai, Toshimitsu
Motomiya, Tomoko
Kano, Takeshi
Nagata, Tsutae
Peck-Radosavljevic, Markus
HEPATOLOGY, 2017, 66 (06) : 1254A - 1254A
[45] Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
Raz, Itamar
Fonseca, Vivian
Kipnes, Mark
Durrwell, Laurence
Hoekstra, John
Boldrin, Mark
Balena, Raffaella
DIABETES CARE, 2012, 35 (03) : 485 - 487
[46] EFFICACY AND SAFETY OF ACT-280778, A DUAL L- AND T-TYPE CALCIUM CHANNEL BLOCKER, IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL HYPERTENSION: RESULTS FROM A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL (REDUCE-1)
Dingemanse, J.
Otasevic, P.
Shakeri-Nejad, K.
Klainman, E.
Putnikovic, B.
Kracker, H.
Mueller, M.
Zimlichman, R.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S33 - S33
[47] Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
Moreno, Christophe
Ferenci, Peter
Asselah, Tarik
Foster, Graham
Zeuzem, Stefan
Sarrazin, Christoph
Maevskaya, Marina
Calinas, Filipe
Enrique Morano, Luis
Crespo, Javier
Dufour, Jean-Francois
Bourliere, Marc
Agarwal, Kosh
Forton, Daniel
Schuchmann, Marcus
Zehnter, Elmar
Nishigushi, Shuhei
Omata, Masao
Stern, Jerry
Datsenko, Yakov
Scherer, Joseph
Quinson, Anne-Marie
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S145 - S145
[48] Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study
Saba, N. F.
Harrington, K.
Licitra, L.
Machiels, J. P.
Huang, M.
Xu, F.
Patel, P.
Haddad, R. I.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E40 - E41
[49] Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-blind, active-controlled, phase 3 study
Mori, Takuya
Murasaki, Kagari
Hayashi, Koichi
Yokoyama, Yuichi
JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 704 - 714
[50] Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Scarisbrick, Julia
Horwitz, Steven M.
Prince, H. Miles
Whittaker, Sean
Duvic, Madeleine
Kim, Youn H.
Quaglino, Pietro
Zinzani, Pier Luigi
Bechter, Oliver
Eradat, Herbert
Pinter-Brown, Lauren
Akilov, Oleg
Geskin, Larisa
Sanches, Jose
Ortiz-Romero, Pablo
Lisano, Julie
Brown, Lisa
Bunn, Veronica
Little, Meredith
Dummer, Reinhard
EUROPEAN JOURNAL OF CANCER, 2019, 119 : S31 - S31

← 1 2 3 4 5 →